Showing 2661-2670 of 3315 results for "".
- RxSight Announces Pricing of Public Offering of Common Stockhttps://modernod.com/news/rxsight-announces-pricing-of-public-offering-of-common-stock/2481395/RxSight, maker of the RxSight Light Adjustable Lens system, announced it has priced its underwritten public offering. RxSight expects to sell 4 million shares of its common stock at a price to the public of $12.50 per share. RxSight has granted the underwriter a 30-day op
- Viridian Appoints Scott Myers as President and Chief Executive Officerhttps://modernod.com/news/viridian-appoints-scott-myers-as-president-and-chief-executive-officer/2481388/Viridian Therapeutics has appointed Scott Myers as President and Chief Executive Officer, as well as a member of the Board of Directors, effective February 6, 2023. He succeeds Jonathan Violin, PhD, who has led Viridian since its inception in 2020. “Our progres
- VSP Vision Names New President of VSP Ventureshttps://modernod.com/news/kathleen-steele-named-president-of-vsp-ventures/2481370/VSP Vision announced that Kathleen Steele has been named president of VSP Ventures. In the role, Ms. Steele will lead the company’s business unit that provides care-focused choices for doctors of optometry looking for practice transition options. She will report to Kate Renwick-Es
- Johns Hopkins Researchers Explore Why Episodes of Low Blood Sugar Worsen Eye Disease in People with Diabeteshttps://modernod.com/news/johns-hopkins-researchers-explore-why-episodes-of-low-blood-sugar-worsen-eye-disease-in-people-with-diabetes/2481367/Researchers at Johns Hopkins Medicine say they have linked low blood sugar levels in people with diabetes with a molecular pathway that is turned on in oxygen-starved cells in the eye. The research, involving human and mouse eye cells and intact retinas grown in a low sugar (low glucose
- Study: Maintaining the Enzyme ACE2 in the Gut May Prevent Diabetic Blindnesshttps://modernod.com/news/type-1-diabetes-maintaining-the-enzyme-ace2-in-the-gut-prevents-diabetic-blindness/2481360/A new study from the University of Alabama at Birmingham shows that the progressive damage to blood vessels in the light-sensitive tissue at the back of the eye may be due to a leaky small intestine that weakens the barrier between gut bacteria and the blood system. The study publi
- Staar Surgical Announces Partnership with Actress Peyton Listhttps://modernod.com/news/staar-surgical-announces-partnership-with-actress-peyton-list/2481344/Staar Surgical announced a partnership with actress and beauty entrepreneur, Peyton List, to promote the EVO Implantable Collamer Lenses (EVO), which recevied FDA approval in 2022 for the correction of myopia with or without astigmatism. In December 2022, Ms. Li
- Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Eye Care Divisionhttps://modernod.com/news/viatris-closes-acquisitions-of-oyster-point-pharma-and-famy-life-sciences-establishing-new-viatris-eye-care-division-1/2481326/Viatris announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. The transaction was first announced on November 7. Former Oyster Point Pharma CEO, Jeffrey Nau, PhD, MMS, will lead the new di
- Shamir Glacier Plus Metaform on Transitions Signature GEN 8 Brown and Grey Now Availablehttps://modernod.com/news/shamir-glacier-plus-metaform-on-transitions-signature-gen-8-brown-and-grey-now-available/2481325/Shamir announced the launch of Shamir Glacier Plus Metaform, a new lens coating that is designed to remove compromises experienced with other lenses. According to Shamir, features of the coating include: Up to 20% thinner & lighter t
- Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCEDhttps://modernod.com/news/kala-pharmaceuticals-announces-fda-acceptance-of-ind-application-for-kpi-012-for-the-treatment-of-pced/2481312/Kala Pharmaceuticals announced that the FDA has accepted an investigational new drug (IND) application for the company’s lead product candidate, KPI-012, a human mesenchymal stem cell secretome (MSC-S), initially in development for the treatment of persistent corneal epithelial de
- Melt Pharmaceuticals’ MELT-300 Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Studyhttps://modernod.com/news/melt-pharmaceuticals-melt-300-achieves-primary-sedation-endpoint-in-phase-2-pivotal-efficacy-and-safety-study/2481307/Melt Pharmaceuticals announced topline results of its phase 2 pivotal efficacy and safety study for its lead product candidate, MELT-300, a sublingual, needle- and opioid-free patented formulation for procedural sedation during cataract surgery. Based on the outcome of the MELT-300 data, the